Open AccessReal-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Author(s) -
Eva Brunnemer,
Julia Wälscher,
Svenja Tenenbaum,
Julia Hausmanns,
Karen Schulze,
Marianne Seiter,
Claus Peter Heußel,
Arne Warth,
Felix J.F. Herth,
Michael Kreuter
Publication year - 2018
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000485933
Subject(s) - nintedanib , medicine , idiopathic pulmonary fibrosis , vital capacity , gastroenterology , pirfenidone , pulmonary function testing , placebo , adverse effect , interstitial lung disease , lung , diffusing capacity , lung function , pathology , alternative medicine
Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited.